← Search & browse all drugs

oxomemazine

R06AD08

Forms & Strengths

Oral solution: 0.33 mg/mL
Syrup: 0.05% (0.5 mg/mL)

Adult Dosing

Dry and irritative cough: 10 mg to 20 mg per dose, 2 to 4 times daily
Maximum daily dose: 80 mg

Pediatric Dosing

Children over 2 years: 0.125 mg/kg to 0.25 mg/kg per dose, 3 to 4 times daily
Not recommended in infants under 2 years of age due to risk of fatal respiratory depression

Indications

Symptomatic treatment of non-productive (dry) coughs, particularly nocturnal or irritative
Allergic rhinitis and allergic manifestations due to H1 antihistaminic properties

Mechanism of Action

First-generation phenothiazine antihistamine with strong H1-receptor antagonistic properties
Exhibits significant central anticholinergic and sedative effects contributing to antitussive action

Contraindications

Hypersensitivity to oxomemazine or other phenothiazines
Children under 2 years of age
History of agranulocytosis
Risk of urinary retention related to urethroprostatic disorders
Risk of angle-closure glaucoma
Concurrent use with alcohol or central nervous system depressants

Adverse Reactions

Sedation and somnolence (most common)
Anticholinergic effects: dry mouth, blurred vision, urinary retention, constipation, tachycardia
Orthostatic hypotension
Dizziness, confusion, or paradoxical excitation in pediatric or elderly patients
Photosensitization
Rare: leukopenia, agranulocytosis, respiratory depression

Drug Interactions

Central nervous system depressants (opioids, barbiturates, benzodiazepines, sedatives): enhanced sedation and respiratory depression
Alcohol: potentiation of sedative effects
Anticholinergic drugs (atropine, tricyclic antidepressants): additive anticholinergic adverse effects
Strong CYP inhibitors/inducers may alter metabolism

Curated Content: Needs Vetting Before Put to Clinical Use